KR20030084895A - 항원 유사성을 이용하여 감염 인자를 검출하는 방법 - Google Patents

항원 유사성을 이용하여 감염 인자를 검출하는 방법 Download PDF

Info

Publication number: KR20030084895A
Authority: KR; South Korea
Prior art keywords: phage; collection; serum; hcv; clones
Prior art date: 2000-11-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR10-2003-7006153A

Other languages

English (en)

Korean (ko)

Inventor

펠리시프랑코

가르가노니콜라

미넨코바올가

모나시파올로

Original Assignee

켄톤 에스.알.엘.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-03

Filing date

2000-11-03

Publication date

2003-11-01

2000-11-03 Application filed by 켄톤 에스.알.엘. filed Critical 켄톤 에스.알.엘.

2003-11-01 Publication of KR20030084895A publication Critical patent/KR20030084895A/ko

Status Ceased legal-status Critical Current

Links

239000000427 antigen Substances 0.000 title claims abstract description 40
108091007433 antigens Proteins 0.000 title claims abstract description 37
102000036639 antigens Human genes 0.000 title claims abstract description 37
238000001514 detection method Methods 0.000 title claims abstract description 16
239000012678 infectious agent Substances 0.000 title description 4
210000002966 serum Anatomy 0.000 claims abstract description 100
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 95
238000000034 method Methods 0.000 claims abstract description 47
239000003446 ligand Substances 0.000 claims abstract description 36
230000000890 antigenic effect Effects 0.000 claims abstract description 11
238000012216 screening Methods 0.000 claims abstract description 9
238000000338 in vitro Methods 0.000 claims abstract description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 51
230000009257 reactivity Effects 0.000 claims description 31
239000000203 mixture Substances 0.000 claims description 30
238000003556 assay Methods 0.000 claims description 19
150000001413 amino acids Chemical class 0.000 claims description 15
208000015181 infectious disease Diseases 0.000 claims description 15
238000012360 testing method Methods 0.000 claims description 12
235000001014 amino acid Nutrition 0.000 claims description 11
238000004091 panning Methods 0.000 claims description 10
230000003248 secreting effect Effects 0.000 claims description 7
229960005486 vaccine Drugs 0.000 claims description 7
208000005176 Hepatitis C Diseases 0.000 claims description 6
238000003018 immunoassay Methods 0.000 claims description 6
238000009007 Diagnostic Kit Methods 0.000 claims description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 5
238000006243 chemical reaction Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
230000035800 maturation Effects 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
230000003362 replicative effect Effects 0.000 claims description 3
238000003780 insertion Methods 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
230000035772 mutation Effects 0.000 abstract 1
241000711549 Hepacivirus C Species 0.000 description 55
238000002965 ELISA Methods 0.000 description 30
241000282414 Homo sapiens Species 0.000 description 16
230000000903 blocking effect Effects 0.000 description 11
239000000872 buffer Substances 0.000 description 10
238000004458 analytical method Methods 0.000 description 9
230000004043 responsiveness Effects 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 8
238000003745 diagnosis Methods 0.000 description 7
238000011534 incubation Methods 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
239000011534 wash buffer Substances 0.000 description 6
241000700605 Viruses Species 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
108010067902 Peptide Library Proteins 0.000 description 4
101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
230000008348 humoral response Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000283707 Capra Species 0.000 description 3
108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 3
101710144111 Non-structural protein 3 Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108010032595 Antibody Binding Sites Proteins 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
241000724791 Filamentous phage Species 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000001261 affinity purification Methods 0.000 description 2
238000003314 affinity selection Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000234 capsid Anatomy 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000002245 particle Substances 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
241000347487 Adamsia Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000003849 Cytochrome P450 Human genes 0.000 description 1
101100028477 Drosophila melanogaster Pak gene Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
206010019728 Hepatitis alcoholic Diseases 0.000 description 1
101710121996 Hexon protein p72 Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000001188 anti-phage Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000010310 bacterial transformation Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000013461 design Methods 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000009448 modified atmosphere packaging Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
235000019837 monoammonium phosphate Nutrition 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
231100000654 protein toxin Toxicity 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000012340 reverse transcriptase PCR Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000003827 upregulation Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Pathology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

KR10-2003-7006153A 2000-11-03 2000-11-03 항원 유사성을 이용하여 감염 인자를 검출하는 방법 Ceased KR20030084895A (ko)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/IT2000/000442 WO2002037115A1 (fr)	2000-11-03	2000-11-03	Détection d'agents infectieux au moyen de mimiques d'antigènes

Publications (1)

Publication Number	Publication Date
KR20030084895A true KR20030084895A (ko)	2003-11-01

Family

ID=11133576

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR10-2003-7006153A Ceased KR20030084895A (ko)	2000-11-03	2000-11-03	항원 유사성을 이용하여 감염 인자를 검출하는 방법

Country Status (12)

Country	Link
EP (1)	EP1332369A1 (fr)
JP (1)	JP2004513346A (fr)
KR (1)	KR20030084895A (fr)
CN (1)	CN1455866A (fr)
AU (1)	AU2001218836A1 (fr)
BR (1)	BR0017366A (fr)
CA (1)	CA2427602A1 (fr)
HU (1)	HUP0302103A3 (fr)
MX (1)	MXPA03003794A (fr)
PL (1)	PL364832A1 (fr)
SK (1)	SK5362003A3 (fr)
WO (1)	WO2002037115A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2108656A1 (fr)	2008-03-19	2009-10-14	Beninati, Concetta	Fragments de protéines antigéniques de streptococcus pneumoniae
WO2009158682A2 (fr) *	2008-06-27	2009-12-30	Watkinson D Tobin	Compositions et procédés pour diagnostiquer et traiter des troubles pathogènes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2172305A1 (fr) *	1995-03-30	1996-10-01	Muneo Aoyama	Peptide antigenique multiple, renfermant au moins deux peptides associes du virus de l'hepatite c
WO1999058561A1 (fr) *	1998-05-14	1999-11-18	Pasteur Merieux Serums & Vaccins	Mimotopes du virus de l'hepatite c

2000
- 2000-11-03 EP EP00981607A patent/EP1332369A1/fr not_active Withdrawn
- 2000-11-03 CA CA002427602A patent/CA2427602A1/fr not_active Abandoned
- 2000-11-03 HU HU0302103A patent/HUP0302103A3/hu unknown
- 2000-11-03 WO PCT/IT2000/000442 patent/WO2002037115A1/fr not_active Ceased
- 2000-11-03 SK SK536-2003A patent/SK5362003A3/sk not_active Application Discontinuation
- 2000-11-03 MX MXPA03003794A patent/MXPA03003794A/es not_active Application Discontinuation
- 2000-11-03 BR BR0017366-5A patent/BR0017366A/pt not_active IP Right Cessation
- 2000-11-03 PL PL00364832A patent/PL364832A1/xx unknown
- 2000-11-03 JP JP2002539818A patent/JP2004513346A/ja active Pending
- 2000-11-03 CN CN00820000A patent/CN1455866A/zh active Pending
- 2000-11-03 KR KR10-2003-7006153A patent/KR20030084895A/ko not_active Ceased
- 2000-11-03 AU AU2001218836A patent/AU2001218836A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SK5362003A3 (en)	2003-09-11
PL364832A1 (en)	2004-12-27
EP1332369A1 (fr)	2003-08-06
JP2004513346A (ja)	2004-04-30
CA2427602A1 (fr)	2002-05-10
HUP0302103A3 (en)	2007-03-28
HUP0302103A2 (hu)	2003-09-29
WO2002037115A1 (fr)	2002-05-10
MXPA03003794A (es)	2004-10-15
BR0017366A (pt)	2004-06-15
AU2001218836A1 (en)	2002-05-15
CN1455866A (zh)	2003-11-12

Publication	Publication Date	Title
Folgori et al.	1994	A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera.
US8728723B2 (en)	2014-05-20	Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism
JP3188717B2 (ja)	2001-07-16	Ｃ型肝炎アッセイ
JPH04330098A (ja)	1992-11-18	Ｈｃｖ−特異的ペプチド、それらのための剤およびそれらの使用
JP3657515B2 (ja)	2005-06-08	ウイルスエンベロープ蛋白中のエピトープおよびこれらのエピトープに対して指向された特異的抗体：宿主組織中のｈｃｖウイルス抗原の検出のための使用
JP3751315B2 (ja)	2006-03-01	Ｃ型肝炎ウイルス４、５及び６型
EP1328811B1 (fr)	2005-08-31	Composition d'antigene mosaique du virus de l'hepatite c (vhc)
EP0642666B2 (fr)	2004-08-11	Analyse de detection de l'hepatite c
KR100240514B1 (ko)	2000-01-15	멀티머 항원을 사용하는 특이적 면역글로불린의 측정방법
JPH10502165A (ja)	1998-02-24	合成ペプチド−改良イムノアッセイを使用する異なるｈｉｖ遺伝子型の検出
JP4173204B2 (ja)	2008-10-29	Ｈｃｍｖ特異的ペプチド、その薬剤および使用
JPH08510063A (ja)	1996-10-22	リコンビナントタンパクおよび合成ペプチド試薬を用いるｈｉｖイムノアッセイ
Minenkova et al.	2001	ADAM‐HCV, a new‐concept diagnostic assay for antibodies to hepatitis C virus in serum
KR20030084895A (ko)	2003-11-01	항원 유사성을 이용하여 감염 인자를 검출하는 방법
US6447992B1 (en)	2002-09-10	Method for serological typing using type-specific antigens
CZ20031044A3 (cs)	2003-10-15	Způsob diagnostikování infekčních agens s využitím antigenových mimetik
IE922548A1 (en)	1993-02-10	Non-a, non-b peptide
JP2655205B2 (ja)	1997-09-17	非ａ非ｂ肝炎のアッセイ
EP0536838A2 (fr)	1993-04-14	Peptides non-A, non-B
WO1993011158A2 (fr)	1993-06-10	Peptides non-a, non-b
Bondarenko et al.	1999	Lack of correlation between sensitivity characteristics of the tests for hepatitis C virus antibodies estimated with serially diluted and natural low-reactive control specimens
HK1059307A (en)	2004-06-25	Detection of infectious agents using antigen mimics
JPH04221398A (ja)	1992-08-11	非ａ非ｂ型肝炎ウイルスに対する抗体と免疫化学反応するペプチド
SE503627C2 (sv)	1996-07-22	Peptid, diagnostiskt antigen och förfarande för hepatit C diagnos
AU2007200598A1 (en)	2007-03-08	A hepatitis C antigen - antibody combination assay for the early detection of HCV infection

Legal Events

Date	Code	Title	Description
2003-05-02	PA0105	International application	Patent event date: 20030502 Patent event code: PA01051R01D Comment text: International Patent Application
2003-11-01	PG1501	Laying open of application
2005-09-27	A201	Request for examination
2005-09-27	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20050927 Comment text: Request for Examination of Application
2006-08-30	E902	Notification of reason for refusal
2006-08-30	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20060830 Patent event code: PE09021S01D
2006-12-21	E601	Decision to refuse application
2006-12-21	PE0601	Decision on rejection of patent	Patent event date: 20061221 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20060830 Comment text: Notification of reason for refusal Patent event code: PE06011S01I